Viewing nowCombinationJanualin Duo Tablet 50/500 mg
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Il Yang Pharmaceutical Co., Ltd.

MFDS item code 202200305 · Approved 2022.01.19 · Insurance code 641706190
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication is used in conjunction with dietary and exercise therapy to assist in controlling blood sugar levels in patients with type 2 diabetes. It is effective for patients starting treatment who cannot achieve adequate blood sugar control with monotherapy. This medication can be used when monotherapy with either metformin or sitagliptin is insufficient, or when replacing combination therapy of both drugs. Moreover, it can be administered in conjunction when blood sugar control is inadequate with metformin combined with sulfonylurea or metformin with thiazolidinedione. This medication can also be added to insulin therapy when used in conjunction with metformin does not provide sufficient control. Overall, this medication helps improve blood sugar control in various diabetes treatment situations.
For antidiabetic therapy, determine the dose of this medicine based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. The initial dose of this medicine should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no previous history of antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, or for whom sitagliptin monotherapy does not provide adequate glycemic control, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Patients Who Must Not Take This Medicine). 2. Patients receiving metformin: - For patients who do not achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg) together with the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin. 3. Patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg); the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When administered with a sulfonylurea or insulin, consider reducing the dose of the sulfonylurea or insulin to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this medicine. Any change in treatment for type 2 diabetes may alter glycemic control; use caution and ensure appropriate monitoring. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment with this medicine should not be initiated because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, discontinue this medicine immediately. Patients with hepatic impairment This medicine must not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Must Not Take This Medicine).
This medication contains two components used for diabetes treatment: sitagliptin and metformin. One of the most important precautions while taking this medication is the risk of hypersensitivity reactions. Serious allergic reactions such as skin rashes, hives, and breathing difficulties may occur after taking this medication, so if these symptoms arise, discontinue use immediately and consult a physician. Moreover, this medication may cause pancreatitis, an inflammation of the pancreas, so if symptoms such as abdominal pain, nausea, vomiting, or fever appear while taking it, seek immediate medical attention. The metformin component can lead to lactic acidosis, a rare but very serious side effect, characterized by fatigue, difficulty breathing, or abdominal pain. If these symptoms occur, discontinue use immediately and seek emergency treatment. This medication is not administered to patients with severely reduced kidney function, severe infections, acute heart failure, or acute myocardial infarction. It is also not used in pregnant or nursing women. Regular monitoring of kidney function is essential during treatment, and the medication should be temporarily halted in cases of dehydration or severe vomiting, diarrhea, etc. This medication may cause hypoglycemia, particularly when taken with insulin or sulfonylureas, so blood sugar levels should be frequently checked, and immediate action should be taken if symptoms occur. Furthermore, excessive alcohol consumption should be avoided while taking this medication, and in cases of upcoming surgery, the medication should be discontinued 48 hours prior, resuming only after kidney function has returned to normal. Blistering on the skin or severe joint pain may occur, so inform a physician immediately and seek treatment if these symptoms arise. Finally, the safety and efficacy of this medication have not been confirmed for children and adolescents under 18 years of age, so it is not used in this population. Regular blood tests and kidney function assessments are of utmost importance while undergoing treatment to check for any abnormalities.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container that is well-ventilated, at room temperature between 1 and 30 degrees Celsius. Proper storage will help maintain the medication's effectiveness for a longer time.
Bright pink oval film-coated tablet
30 tablets/box [(10 tablets/PTP x 3)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Il Yang Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Eden Pharma Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.